The specialty chemicals company LANXESS has successfully placed a 6-year-tenor euro benchmark bond with a coupon of 0.0 per cent in the European capital market. LANXESS will use the funds to finance the planned acquisition of the microbial control business of US-based chemical company IFF.
The new bond is listed on the Luxembourg Stock Exchange in denominations of EUR 1,000.
“We have secured a first step of financing already quickly after the announcement of the acquisition of IFF Microbial Control and are happy about the very receptive reaction of the capital market to our offering,” said LANXESS Chief Financial Officer Michael Pontzen.
LANXESS’ issuer ratings are currently Baa2 (Moody’s), BBB (Standard & Poor’s) and BBB+ (Scope). A bank consortium of active joint bookrunners comprising Citi, Société Générale and Unicredit was mandated to place the bond.
LANXESS is a leading specialty chemicals company with sales of EUR 6.1 billion in 2020. The company currently has about 14,800 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.